Alessa is currently conducting their first in-man clinical study of Biolen™ PC, a minimally-invasive, drug delivery implantable system with patients with prostate cancer. Biolen PC is designed to administer anti-androgen drugs to the tumor in the prostate through a sustained, localized system – without systemic exposure.
The primary objectives of the study are to assess the safety and patient tolerance of Biolen PC. The study is being conducted at several clinical institutions in Australia and New Zealand. We are looking to recruit men over the age of 35 who:
- Have biopsy confirmed prostate cancer – Gleason score 3+4 or higher
- Are scheduled to undergo surgery to remove the prostate
- Are willing and able to undergo MRI follow-up imaging
Alessa will also be evaluating whether the same approach can be used to treat benign prostatic hyperplasia.